Blog
RSS FeedPosted by Michael Wonder on 13 Nov 2024
Alectinib hydrochloride for the adjuvant treatment of patients with ALK positive non-small-cell lung cancer
13 November 2024 - NICE has published final evidence-based recommendations on the use of alectinib hydrochloride for the adjuvant treatment ...
Posted by Michael Wonder on 06 Nov 2024
Fenfluramine hydrochloride for the treatment of patients 2 years of age and older with seizures associated with Lennox–Gastaut syndrome
5 November 2024 - Following an appeal, NICE has published further draft guidance on the use of using fenfluramine hydrochloride ...
Posted by Michael Wonder on 29 Oct 2024
People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy
29 October 2024 - Hundreds of people with a rare form of blood cancer could be set to benefit after NICE ...
Posted by Michael Wonder on 24 Oct 2024
Quizartinib dihydrochloride for the induction, consolidation and maintenance treatment of adults with newly diagnosed FLT3-ITD positive acute myeloid leukaemia
23 October 2024 - NICE has published final evidence-based recommendations on the use of quizartinib dihydrochloride (Vanflyta) for the induction, ...
Posted by Michael Wonder on 23 Oct 2024
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
23 October 2024 - More evidence is needed on the clinical and cost effectiveness of donanemab, a new treatment for mild ...
Posted by Michael Wonder on 23 Oct 2024
Danicopan in combination with ravulizumab or eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria (final guidance)
23 October 2024 - NICE has published final evidence-based recommendations on the use of danicopan (Voydeya) in combination with ravulizumab ...
Posted by Michael Wonder on 25 Sep 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments (final guidance)
25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for ...
Posted by Michael Wonder on 19 Sep 2024
Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia
19 September 2024 - Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by NICE for certain cases of acute myeloid leukaemia. ...
Posted by Michael Wonder on 17 Sep 2024
Rucaparib camsylate for the maintenance treatment of patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (final guidance)
17 September 2024 - NICE has published final evidence-based recommendations on the use of rucaparib camsylate (Rubraca) for the maintenance ...
Posted by Michael Wonder on 12 Sep 2024
Empagliflozin for the treatment of adolescents with type 2 diabetes mellitus
12 September 2024 - NICE is unable to make a recommendation on the use of empagliflozin (Jardiance) in the NHS for ...
Posted by Michael Wonder on 12 Sep 2024
Futibatinib for previously treated patients with advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
11 September 2024 - NICE has published final evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 ...
Posted by Michael Wonder on 12 Sep 2024
Faricimab for the treatment of patients with visual impairment caused by macular oedema after retinal vein occlusion
11 September 2024 - NICE has published final evidence-based recommendations on the use of faricimab (Vabysmo) for the treatment of ...
Posted by Michael Wonder on 11 Sep 2024
Exagamglogene autotemcel for the treatment of patients 12 years of age and older with transfusion-dependent beta-thalassaemia
11 September 2024 - NICE has published final evidence-based recommendations on the use of exagamglogene autotemcel (Casgevy) for the treatment ...
Posted by Michael Wonder on 11 Sep 2024
Evinacumab for the treatment of patients 12 years of age and older with homozygous familial hypercholesterolaemia
11 September 2024 - NICE has published final evidence-based recommendations on the use of evinacumab (Evkeeza) for the treatment of ...
Posted by Michael Wonder on 05 Sep 2024
Adults with von Hippel-Lindau disease to benefit from new treatment
5 September 2024 - NICE has recommended belzutifan for some adults with von Hippel-Lindau disease, in final draft guidance, which could ...